Dendreon Corporation Announces Executive Management Promotions; Mitchell H. Gold, M.D. Elected to Board of Directors.Business/Technology Editors, Health/Medical Writers BIOWIRE2K SEATTLE--(BW HealthWire)--May 30, 2002 Dendreon Corporation (Nasdaq:DNDN) announced today that Mitchell H. Gold, M.D., has been promoted to Chief Business Officer. Dr. Gold was previously Vice President of Business Development. In his new and expanded role, he will oversee key operating areas of the company, including business development, public relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most and investor-related activities. In addition, Dr. Gold has been elected to the company's Board of Directors. The company also promoted Deborah Elvins to Vice President of Legal Affairs. In her new role, Elvins will have increased responsibilities for licensing, securities and human resources The fancy word for "people." The human resources department within an organization, years ago known as the "personnel department," manages the administrative aspects of the employees. , as well as patent, contract and real estate matters. "Since joining the company a little over a year ago, Mitchell and Deborah have both made outstanding contributions," said Christopher S. Henney, Ph.D., D.Sc., chief executive officer. "As we continue to grow and diversify, Mitchell's leadership role both internally and at the level of the board of directors, which he has now joined, will be even more important in enabling us to grow and to efficiently capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. our expanding asset base." Dendreon currently has three products involving approximately a dozen clinical trials. Eight new product candidates are currently in preclinical development, several of which are set to begin clinical trials over the next one to two years. Prior to joining Dendreon in 2001, Dr. Gold served as vice president of business development and vice president of sales and marketing for Data Critical Corporation, now a division of General Electric. Before that, he was the founder, president and chief executive officer of Elixis Corporation, a leader in healthcare information technology applications. Dr. Gold was a urologist Urologist A physician who deals with the study and treatment of disorders of the urinary tract in women and the urogenital system in men. Mentioned in: Congenital Bladder Anomalies, Lithotripsy, Men's Health, Overactive Bladder urologist at the University of Washington in Seattle. He serves on the boards of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Institute and Xenotope Diagnostics of Palo Alto, Calif. Before joining Dendreon in 2001, Ms. Elvins was a partner with Stoel Rives Language Rive (plural : rives) is a French word meaning "bank" (of a river). Geography Rives is the name of several places: France Rives is the name of 2 communes in France:
Dendreon Corporation is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon's lead product, Provenge(TM), a therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for the treatment of prostate cancer, has advanced to Phase III clinical trials. Dendreon has two other therapeutic cancer vaccine candidates in clinical trials -- Mylovenge(TM), for the treatment of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , in Phase II trials; and APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024, for the treatment of breast, ovarian and colon cancers, in Phase I trials. Dendreon's product pipeline also includes monoclonal antibodies and a pathway to small molecules. For more information, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, the risk of loss of key employees, risks associated with the completing or failing to complete clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk the company may not satisfy regulatory requirements or that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the uncertainty of Dendreon's future access to capital, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion